Quantcast

Latest photodynamic therapy Stories

2014-09-17 08:28:52

Pivotal Phase 3 Clinical Trial Targeted to Begin in First Half of 2015 PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its...

2014-09-15 23:01:28

Ondine's President and Chief Technology Officer Dr. Nicolas Loebel will be presenting at the 10th International Symposium on Photodynamic Therapy & Photodiagnosis in Clinical Practice Vancouver, BC (PRWEB) September 15, 2014 Ondine Biomedical Inc. is pleased to announce that Dr. Nicolas Loebel, its President and Chief Technology Officer, will be presenting at the 10th International Symposium on Photodynamic Therapy (PDT) and Photodiagnosis in Clinical Practice. The 2014 Symposium,...

2014-09-12 12:25:28

Laser Approved for Treatment of PCV, CSR CLERMONT-FERRAND, France, Sept. 12, 2014 /PRNewswire/ -- Quantel Medical today announced CE Mark approval for its Vitra(TM) PDT photodynamic therapy laser platform, for the treatment of polypoidal choroidal vasculopathy (PCV) and central serous retinopathy (CSR). Quantel, the sole manufacturer of this laser technology, plans to begin commercializing the laser platform immediately in countries requiring CE registration. PCV, a disease of the...

2014-09-05 08:23:11

Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). SGX301 is poised to enter...

2014-09-02 08:29:06

TORONTO AND CHICAGO, Sept. 2, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle"), a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN(®) (porfimer sodium)...

2014-08-11 08:28:38

TORONTO, ON and CHICAGO, IL, Aug. 11, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate...

2014-08-05 08:33:22

Thomas Jefferson University Hospital is first site opened, more sites scheduled in August TORONTO AND CHICAGO, Aug. 5, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, and its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, today...

2014-07-15 08:28:50

TORONTO, July 15, 2014 /CNW/ - The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). For eligible patients the positive impact of Metvix PDT cannot be overestimated in pre-cancerous AK (Actinic Keratoses) and superficial BCC (Basal Cell...

2014-07-14 23:06:45

If an NIH grant can help validate the effectiveness of photodynamic therapy (PDT), more mesothelioma patients may have access to it in the future. Raleigh, NC (PRWEB) July 14, 2014 The NIH is giving $8 million dollars to researchers at the University of Pennsylvania to fund a clinical trial on light-based therapy in mesothelioma surgical patients. Click here to read Surviving Mesothelioma’s newly-posted article on the research. Scientists at the University of Pennsylvania plan to use...

2014-04-16 14:11:59

A University of Texas at Arlington physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead happened upon an advance in photodynamic cancer therapy. Wei Chen, professor of physics and co-director of UT Arlington's Center for Security Advances Via Applied Nanotechnology, was testing a copper-cysteamine complex created in his lab when he discovered unexplained decreases in its luminescence, or light emitting power, over a...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'